
Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE:ZH, SEHK:2390), Roborock (SHSE:688169), UBTech (SEHK:9880), WeRide (NASDAQ:WRD), HyperStrong (SHSE:688411), Insta360 (SHSE:688775), Unisound (SEHK:9678), Gan & Lee Pharmaceuticals (SHSE:603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE:688520), Yuanxin Technology, Insilico Medicine, Medilink Therapeutics, LaNova Medicines, zai, StepFun, among many others.
我們正在追蹤 Qiming Venture Partners 的市場擴張
Qiming Venture Partners 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
Qiming Venture Partners你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Qiming Venture Partners 業務、市場及增長訊號的快速解答。
